Targeted oncogene inactivation by small molecule inhibitors can be very effective but tumor recurrence is a frequent problem in the clinic. Therapy by inactivation of the cancer-driving oncogene in transplanted tumors was shown to be augmented in the presence of T cells. However, these experiments did not take into account the long-term, usually tolerogenic, interaction of de novo malignancies with the immune system. Here, we employed mice, in which SV40 large T (Tag) and firefly luciferase (Luc) as fusion protein (TagLuc) could be regulated with the Tet-on system and upon activation resulted in tumors after a long latency. TagLuc inactivation induced profound tumor regression, demonstrating sustained oncogene addiction. While tumor relapse after TagLuc inactivation was prevented in immunocompetent mice bearing transplanted tumors, autochthonous tumors relapsed or recurred after therapy discontinuation indicating that the immune system that coevolved with the malignancy over an extended period of time lost the potency to mount an efficient anti-tumor immune response. By contrast, adoptively transferred CD8
Targeted oncogene inactivation by small molecule inhibitors can be very effective but tumor recurrence is a frequent problem in the clinic. Therapy by inactivation of the cancer-driving oncogene in transplanted tumors was shown to be augmented in the presence of T cells. However, these experiments did not take into account the long-term, usually tolerogenic, interaction of de novo malignancies with the immune system. Here, we employed mice, in which SV40 large T (Tag) and firefly luciferase (Luc) as fusion protein (TagLuc) could be regulated with the Tet-on system and upon activation resulted in tumors after a long latency. TagLuc inactivation induced profound tumor regression, demonstrating sustained oncogene addiction. While tumor relapse after TagLuc inactivation was prevented in immunocompetent mice bearing transplanted tumors, autochthonous tumors relapsed or recurred after therapy discontinuation indicating that the immune system that coevolved with the malignancy over an extended period of time lost the potency to mount an efficient anti-tumor immune response. By contrast, adoptively transferred CD8
1 T cells targeting the cancer-driving oncogene eradicated recurrent autochthonous tumors, highlighting a suitable therapy option in a clinically relevant model.
Small molecule inhibitors, designed to inactivate specifically a cancer-driving oncogene have been proven to be highly effective against a variety of cancers in the clinic, e.g. imatinib against BCR-ABL-driven leukemia. 1 Despite the revolutionary success of small molecule inhibitors, drug resistance and, hence, tumor recurrence, is a frequently observed problem in the clinic. Various preclinical animal models revealed that abrogation of the cancer-driving oncogene provokes tumor cell apoptosis, necrosis, senescence, autophagy and/or differentiation, collectively proving oncogene addiction. [2] [3] [4] [5] [6] [7] [8] [9] These cell autonomous mechanisms were long thought to be the primary mechanism responsible for tumor regression. However, recently, it was discovered in a c-myc-driven tumor transplantation model that CD4
1 T cells contribute to sustained tumor regression upon oncogene inactivation by release of chemokines like thrombospondins that remodel the tumor microenvironment, showing that cell extrinsic mechanism, namely cells of the adaptive immune system, contribute to the therapeutic effect of oncogene inactivation. 10 The finding that cancer cell-targeting drugs are not solely tumor cell autonomous but involve T cells was already described for cancer cells equipped with suicide genes that conferred cell death in vivo after application of the corresponding prodrug. T cell-competent mice rejected transplanted cancer cells following prodrug treatment, while tumors relapsed in T cell-deficient mice. 11 Later, it was found that cancer cell death was immunogenic when induced by certain chemotherapeutic drugs, e.g. anthracyclines, and that so treated cancer cells induced T cell-dependent tumor immunity in transplantation models. 12, 13 We showed in a model of large established transplanted tumors that therapeutic efficacy of oncogene inactivation was increased when immunodeficient hosts were reconstituted with T cells. 5 So far, the therapeutic effect of drug-driven anticancer therapies and the contribution of the immune system were mainly analyzed in experimental models with transplanted tumors. These models do not recapitulate the clinical situation because transplanted tumors, although histologically not to discriminate from autochthonous tumors, 14 grow in a short time to large tumors so that the interaction between cancer and immune cells is limited to few weeks. Mouse transplantation models do therefore not recapitulate the long-lasting interplay between cancer and the immune system as it occurs during autochthonous tumor development, which is usually sporadic, clonal and may last for decades in humans. Importantly, the process of cancer cell inoculation is associated with an acute inflammatory response facilitating T cell activation as it unlikely occurs during autochthonous tumor development. It remains therefore questionable if the results obtained from mice transplanted with cancer cells are predictive for cancer patients presenting in the clinic. Here, we established a model in which autochthonous tumors can be induced and treated by oncogene inactivating drugs. With this model, we wanted to answer the question whether the immune system eradicates drug resistant cancer clones during oncogene inactivation therapy and prevents cancer recurrence after therapy discontinuation. 
Material and Methods

Mice
Doxycycline treatment
Dox (0.2 mg/ml; Sigma) was administered by light-protected drinking water supplemented with 5% sucrose changed twice a week, or 1 mg/ml dox was added to the cell culture medium twice a week.
Bioluminescent detection
Mice were anesthetized by isoflurane inhalation using the XGI- 
PCR
To determine recombination status of tumors developed in TTC mice, the following primer pairs were used: #1 forward primer: 5 0 -CGAGGTAGGCGTGTACGGTGG-3 0 , #1 reverse primer: 5 0 -GCAAATTTAAAGCGCTGATGATCC-3 0 , #2 forward primer: 5 0 -CGAGGTAGGCGTGTACGGTGG-3 0 , #2 reverse primer: 5 0 -CGGATGAGCATTCATCAGGCGGG-3 0 .
RT-PCR
RNA was isolated using the RNA isolation kit from Stratec. After DNase treatment, cDNA was reverse transcribed using SuperScriptIII reverse transcriptase and oligo (dT) primer (life technology). To detect tyrosinase transcripts, the following primers (exon spanning) were used: forward primer: 5 0 -TGTACAGAGAAGCGAGTCTTGA-3 0 ; reverse primer: 5 0 -ACAAATGATCTGCCAGGAGGA-3 0 . Beta actin cDNA was amplified using following primer pair: forward primer: 5 0 -ACCACACCTTCTA-CAATGAG-3 0 , reverse primer:
Results
Prevention of transplanted tumor relapse after oncogene inactivation in immunocompetent mice
Tet-TagLuc is a fibrosarcoma cell line derived from a TREloxP stop loxP TagLuc transgenic mouse (see below) and has been described. 5 Tet-TagLuc cells express a fusion protein of SV40 large T (Tag) and firefly luciferase (TagLuc) as cancerdriver under tetracycline promoter control, which can be regulated by doxycycline (dox). Previously, we observed that the frequency of tumor relapse after oncogene inactivation therapy could be reduced in the presence of an intact immune system. 5 To extend the data, we exploited LoxP-TagLuc-pA 16 x CAGrtTA 17 double transgenic mice to enable growth of Tet-TagLuc cells, a regressor cancer cell line in wild type mice. Although LoxP-TagLuc-pA 3 CAG-rtTA mice are tolerant for TagLuc and transactivator antigens, Tet-TagLuc cells injected subcutaneously as single cell suspension were rapidly rejected (Fig. 1a) , indicating the presence of at least one additional transplantation rejection antigen. Transplantation of Tet-TagLuc tumor fragments into LoxP-TagLuc-pA 3 CAG-rtTA mice prevented tumor rejection and tumors grew progressively in all mice. After an average tumor growth period of 28 days (range 22-34 days), tumors reached a size of at least 500 mm 3 and TagLuc inactivation by dox application was started (Figs. 1b and 1c) . TagLuc inactivation resulted in rapid decline of bioluminescence (BL) signal and tumors regressed as followed by BL imaging and caliper measurement, respectively (Figs. 1b and 1c) . Tumors of all Rag -/-mice initially regressed but then relapsed around 1 month after therapy. In contrast, tumors from 6 out of 7 immunocompetent LoxP-TagLuc-pA 3 CAG-rtTA mice did not relapse, although, a small, soft lump at the tumor side remained but did not progress. These results suggested that therapeutic efficacy of oncogene-inactivation therapy depends on the presence of an intact adaptive immune system in a tumor transplantation model, similar as has been reported by Rakhra et al. 10 Furthermore, tumors in LoxP-TagLuc-pA 3 CAG-rtTA mice, although grown for more than one month in the presence of the adaptive immune system, seemed not to have induced tolerance of endogenous tumor-reactive T cells.
TTC mice develop autochthonous tumors
The previous experiment utilized transplantation of cancer cells under the skin that progress in a relatively short period to full-blown tumors. To analyze whether our observations can be extended to tumors initiated and evolved in a primary host with a much longer coevolution between cancer and T cells, we utilized TRE loxP stop loxP TagLuc transgenic mouse lines described previously. 5 Like Tet-TagLuc cells, TRE loxP stop loxP TagLuc transgenic mice contain the TagLuc fusion gene under control of the Tet-promoter, but due to a loxP-flanked stop cassette located between the Tet-promoter and the TagLuc transgene, and the requirement of an active transactivator, expression was prevented in TRE loxP stop loxP TagLuc single transgenic mice (Fig. 2a) . We aimed to achieve TagLuc expression under control of the Tet-on system in a melanocyte-restricted fashion to establish an autochthonous melanoma model. To this end, we crossed TRE loxP stop loxP TagLuc mice derived from two founder lines (F7 and F10) to CAG-rtTA and Tyr::Cre 19 transgenic mice, which express the rtTA and Cre transgenes under the CAG and tyrosinase promoter, respectively (Fig. 2a) (Fig. 2d) with an average tumor latency of 42 weeks (F7) and 35 weeks (F10), respectively (Fig. 2e) . Histological analysis of 14 tumors isolated from eleven TTC mice revealed that the majority of tumors (8/14) were spindle cell tumors, but also pancreatic exocrine 
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adenocarcinomas (n 5 2), mammary adenocarcinomas (n 5 2), papilloma (n 5 1) and a round cell tumor were identified ( Fig. 2f and Table 1 ). In all analyzed tumors, deletion of the stop cassette was detected (Fig. 2g) ; however, none of the isolated tumors showed tyrosinase promoter activity as analyzed by detection of tyrosinase expression (Fig. 2h) . These results suggest that tumors arose from progenitor cells that deleted the stop cassette due to transient tyrosinase promoter activity but these cells did not commit to the melanocyte lineage. We assume that cells from these progenitor cells transformed with higher penetrance than melanocytes so that mice succumbed to nonmelanoma tumors before melanomas could develop.
Autochthonous tumors regress long-term following oncogene inactivation but dormant tumor cells regrow after therapy discontinuation
Tumor-bearing TTC mice with one (n 5 6), two (n 5 3) or more tumors (n 5 1) were subjected to oncogene inactivation therapy by withdrawal of dox-containing drinking water. The average age of mice at the time point of treatment was 298 days (range 166-584 days; Table 2 ). Dox cessation resulted in a rapid decrease of BL signal in all treated mice (n 5 10), declining to <2% (range 0.009-10.5%) of the original signal strength after an average observation period of eight days as shown for seven mice (Figs. 3a and 3b and Supporting Information Figure S1 ). Decline of BL signal was followed by tumor regression, suggesting abundant cell death (Fig. 3c) . From in vitro analysis of cancer cell lines derived from the transgenic mice we know that TagLuc inactivation results in apoptotic cell death in a high proportion of cells (up to >50%; unpublished observation). To analyze whether TagLuc inactivation in autochthonous tumor-bearing mice resulted in complete tumor cell eradication, eight of the ten mice with stably low BL signal over time (average observation period 83 days; range 19-203 days) were subjected again to doxcontaining drinking water. Surprisingly, BL signals increased rapidly in all mice after dox reapplication and tumors developed at the primary tumor site as shown for six mice in Figures 3d-f and Supporting Information Figure S1 . Together, oncogene inactivation in autochthonous tumor-bearing hosts resulted in relatively durable tumor regression, but, more importantly, in all treated mice some tumor cells survived and remained dormant for several weeks and up to six months, able to resume proliferation as soon as TagLuc was reactivated. These results suggest that massive tumor cell death induced by oncogene inactivation does not elicit an immune response potent enough to prevent tumor progression upon oncogene reexpression.
Adoptively transferred T E cells eradicate autochthonous tumors that relapsed after oncogene inactivation
To analyze antigenicity of dormant cancer cells that persisted after oncogene inactivation in the autochthonous host, two tumor-bearing TTC transgenic mice were subjected to TagLuc inactivation therapy (Fig. 4a) . A relatively low but stable FLuc signal at the former tumor site was detectable more than one month after TagLuc inactivation indicating the presence of dormant tumor cells. These mice were irradiated (5 gray) and received monospecific CD8 1 T cells (5 3 10 6 cells) directed against Tag epitope I (T E cells) isolated from immunized TCR-I x ChRLuc double transgenic mice. Expansion and migration of transferred T cells were followed by detection of Renilla luciferase T cell signal by BL imaging over time (Fig. 4a) . Two days after T E cell transfer, an RLuc T cell signal was localized predominantly in cervical lymph nodes and between day 5 and 16 also at the previous tumor site indicating that dormant tumor cells were antigenic and recognized by T E cells in the primary host. Regularly, we observed mice with reappearing BL signal despite continuous oncogene inactivation therapy indicating tumor relapse due to drug resistance. To ask whether transferred T E cells could eradicate autochthonous tumors that escaped oncogene inactivation therapy, we irradiated nine mice with drug resistant tumors and injected 5 3 10
6 T E cells. Tumor rejection by transferred T E cells was monitored by detection of TagLuc tumor signal over time. A reduction in TagLuc activity at the tumor site was observed starting at day four after T E cell transfer and no tumor TagLuc signal was detectable after 12 days in all mice (Figs. 4b and 4c and Supporting Information Figure S2 ). Irradiation alone did not result in tumor eradication (n 5 1, data not shown). Tumor Mouse 1-8: group of mice was subjected to oncogene-inactivation therapy and received dox again after indicated time period. Mouse 9-10: group of mice was subjected to oncogene-inactivation therapy and received T E cells prior developing tumor relapse. RLuc T cell signal was followed. Mouse 11-19: group of mice was subjected to oncogene-inactivation therapy and received T E cell therapy after developing drug-resistant tumors. Mouse 15 and 17 were set on dox again starting four days prior T cell therapy.
rejection was accompanied by robust T E cells expansion, reaching T E cell counts of up to 89% of the total T cell population at day 10 after transfer (average 46.2%) as shown in Figure 4d (n 5 5). While one mouse died seven days after T E cell transfer and decline of TagLuc tumor signal, the remaining eight mice were observed long-term (54-180 days) and tumors did not relapse (Figure 4b ,c, Table 2 and Supporting Information Figure S2 ). Together, dormant tumor cells are Figure S1 and Table 2 .
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antigenic and recognized by transferred T E cells. Furthermore, T E cell therapy proved to be effective to eradicate tumor variants that escaped destruction by oncogene inactivating therapy in primary tumor-bearing hosts. In conclusion, cell death after oncogene inactivation therapy, could neither prevent eventual tumor relapse nor tumor progression after therapy discontinuation in autochthonous tumor bearing hosts.
Discussion
In this study, we analyzed the role of the host immune system for sustained tumor regression after oncogene inactivation therapy. In mice with transplanted tumors, we found a substantial improvement of the therapeutic outcome of oncogene inactivation therapy dependent on the presence of an intact immune system, confirming earlier studies. 5, 10 Since the mice were tolerant for TagLuc and rtTA and Tet-TagLuc cancer cells were rejected as single cell suspension but grew as fragments, 22 we can postulate additional, yet unknown, tumor transplantation rejection antigen(s). These data strongly indicate that cancer cell death induced by oncogene inactivation can be immunogenic under special conditions (the artificial process of cancer cell injection causing acute inflammation) and elicits T cells that reject transplanted cancer cells. However, when the same therapeutic approach was analyzed against autochthonous tumors, tumors frequently relapsed under therapy or recurred after therapy discontinuation. This contrasting effect might be due to the different time period the immune system interacted with the tumor and its microenvironment in the transplanted versus the autochthonous tumor model. The period was relatively short in mice with transplanted tumors but long during autochthonous tumor development. An extended period of time in which T cells encounter their cognate antigen can result in T cell exhaustion that might have hampered the contribution of T cells to the therapeutic effect of oncogene inactivation in mice with autochthonous tumors. This assumption is supported by clinical data and an autochthonous cancer model, demonstrating therapeutic effects by so-called checkpoint inhibitors like anti-PD-1 (ligand) antibodies that unleash tumor-reactive T cells from suppression. [23] [24] [25] In addition, the inflammation created by tumor cell injection in the transplanted tumor model might have increased the number of pre-existing tumor infiltrating T cells facilitating anticancer activity after oncogene inactivation in an artificial manner. Like for other oncogenes including ras, myc, bcr-abl, 2, 4, 26 the growth and survival of cancer cells in the current model remained long-term dependent on the expression of TagLuc. These data are at variance with previous data suggesting that tumors at advanced stage progress independent of Tag expression. 27 However, in this model a version of the transactivator was used that did not allow as tight regulation as rtTA used here. Also in common with other oncogenes, TagLuc inactivation resulted in complete regression of large tumors, yet some cancer cells escaped elimination in a dormant state and could rapidly be reactivated upon drug discontinuation 2, 8, 28 or became drug-resistant, e.g., through mutations in the rtTA conferring dox-unresponsiveness.
5,29
Identifying cancer specific point mutations in tumor samples taken prior oncogene inactivation and engineering T cells with receptors that target these mutations might be a promising approach to combat relapsing tumors after oncogene inactivation therapy in the clinic. In conclusion, in a clinically relevant model, adoptive T cell therapy but not therapy targeting a cancer-driving oncogene can prevent autochthonous tumor recurrence occurring spontaneously or upon treatment discontinuation.
